Discontinuation of systemic medications in Juvenile Idiopathic Arthritis - Risks and Remission: A Systematic Review and Meta-Analysis

OBJECTIVE: Safe and effective strategies for discontinuing systemic medications in children and adolescents with juvenile idiopathic arthritis remain to be defined. This study aimed to determine flare risks following medication discontinuation and to evaluate the impact of disease subtype, remission duration, medication class and discontinuation strategy. METHODS: A systematic review and meta-analysis (PROSPERO-CRD420251168572) was conducted using MEDLINE, EMBASE, and Web of Science evidence synthesis through October 2025. Included studies evaluated medication withdrawal-stopping versus tapering strategies in JIA patients (≤18 years) in remission. Flare was the primary outcome. Random-effects metaanalysis, subgroup analyses, meta-regression, and RoB 2 and ROBINS-I assessments were performed. RESULTS: 18 studies assessing 1,905 patients were included. Flare proportions ranged between 13%-78%, with a pooled estimate of 45% (95%CI:33%-56%;I²=97%). Lower proportions were observed with tapering, including interval spacing (25%[95%CI:8%-42%]) and dose reduction (42%[95%CI:18%-65%]) compared to stopping (57%[95%CI:44%-70%]); differences were not statistically significant. Tapering strategy was the only significant moderator of flare risk (β=0.26, p=0.02), explaining 19% of heterogeneity. Most flares occurred within 6-12 months. Flare proportions also varied by disease subtype, medication class, and remission duration before. Recapture of remission was reported in 50%-100% of patients. Incidence rate sensitivity analyses yielded consistent findings (0.35 flares/person-year). CONCLUSION: Medication discontinuation in JIA carried significant flare risk across both cumulative proportion and person-year rates. The observed heterogeneity primarily mirrored the clinical variation in withdrawal strategies. Differences in flare proportions may reflect residual drug exposure rather than the true strategy effects. The high recapture rate provides reassurance for advancing medication discontinuation approaches.

Authors

Institutions

Publication Details

Journal
The Journal of Rheumatology
Published
2026-11-01
DOI
https://doi.org/10.3899/jrheum.2026-0625
Primary Topic
Autoimmune and Inflammatory Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discontinuation of systemic medications in Juvenile Idiopathic Arthritis - Risks and Remission: A Systematic Review and Meta-Analysis

Sebastiaan J. Vastert, Pegah Noorshargh, Glen Stewart Hazlewood, Susanne M. Benseler et al.
The Journal of Rheumatology
Autoimmune and Inflammatory Disorders Research
article

Discontinuation of systemic medications in Juvenile Idiopathic Arthritis - Risks and Remission: A Systematic Review and Meta-Analysis

Sebastiaan J. Vastert, Pegah Noorshargh, Glen Stewart Hazlewood, Susanne M. Benseler, Rae S. M. Yeung, Joost Frans Swart, Angelina Addae, Deborah Anne Marshall
article en

Abstract

OBJECTIVE: Safe and effective strategies for discontinuing systemic medications in children and adolescents with juvenile idiopathic arthritis remain to be defined. This study aimed to determine flare risks following medication discontinuation and to evaluate the impact of disease subtype, remission duration, medication class and discontinuation strategy. METHODS: A systematic review and meta-analysis (PROSPERO-CRD420251168572) was conducted using MEDLINE, EMBASE, and Web of Science evidence synthesis through October 2025. Included studies evaluated medication withdrawal-stopping versus tapering strategies in JIA patients (≤18 years) in remission. Flare was the primary outcome. Random-effects metaanalysis, subgroup analyses, meta-regression, and RoB 2 and ROBINS-I assessments were performed. RESULTS: 18 studies assessing 1,905 patients were included. Flare proportions ranged between 13%-78%, with a pooled estimate of 45% (95%CI:33%-56%;I²=97%). Lower proportions were observed with tapering, including interval spacing (25%[95%CI:8%-42%]) and dose reduction (42%[95%CI:18%-65%]) compared to stopping (57%[95%CI:44%-70%]); differences were not statistically significant. Tapering strategy was the only significant moderator of flare risk (β=0.26, p=0.02), explaining 19% of heterogeneity. Most flares occurred within 6-12 months. Flare proportions also varied by disease subtype, medication class, and remission duration before. Recapture of remission was reported in 50%-100% of patients. Incidence rate sensitivity analyses yielded consistent findings (0.35 flares/person-year). CONCLUSION: Medication discontinuation in JIA carried significant flare risk across both cumulative proportion and person-year rates. The observed heterogeneity primarily mirrored the clinical variation in withdrawal strategies. Differences in flare proportions may reflect residual drug exposure rather than the true strategy effects. The high recapture rate provides reassurance for advancing medication discontinuation approaches.

The Journal of Rheumatology
University College Dublin (IE), University of Calgary (CA), University of Toronto (CA), Utrecht University (NL), Trinity College Dublin (IE), Hospital for Sick Children (CA), University Medical Center Utrecht (NL), Wilhelmina Children's Hospital (NL), Alberta Children's Hospital Research Institute (CA)
Good health and well-being
Openalex Percentile: Top 12%
Autoimmune and Inflammatory Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon